Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 6/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.34 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18897246 | 0.92 | FGFR4 (0.35) | FGFR4FGFR1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL18897275 | 0.89 | FGFR4 (0.38) | FGFR4FGFR1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL18897412 | 0.81 | ZDHHC20 (0.39) | FGFR4FGFR1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL21166554 | 0.81 | ZDHHC20 (0.39) | FGFR4FGFR1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL18897316 | 0.80 | FGFR4 (0.36) | FGFR4FGFR1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL21166512 | 0.80 | FGFR4 (0.36) | FGFR4FGFR1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL18897315 | 0.80 | FGFR4 (0.37) | FGFR4FGFR1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL21166536 | 0.80 | — | — | |
| SCHEMBL17522200 | 0.76 | TSHR (0.41) | FGFR4FGFR1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL17522183 | 0.76 | TSHR (0.41) | FGFR4FGFR1CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | FGFR4 1590/4885FGFR1 1733/4885CYP3A4 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.